New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients

ConferencepositiveREDUCE-ITPositive

AI Analysis

Summary

A legacy analysis of REDUCE-IT presented at ESC Congress 2026 demonstrated approximately 30% relative risk reduction in highly adherent patients with persistent cardiovascular benefits following icosapent ethyl treatment discontinuation, suggesting a potential legacy effect in secondary prevention.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Legacy analysis presented showing approximately 30% relative risk reduction in highly adherent patients with evidence of persistent cardiovascular benefit following treatment cessation

Importance:6/10

Sentiment:

0.75

cardiovascularicosapent ethyllegacy effectsecondary preventionESC Congressclinical data

Related Companies

$AMRN

Read the original article

Published by GlobeNewswire Clinical Studies on August 28, 2026 12:15 PM

Read Original